SEC Form 4 · accession 0001209191-18-007472
Aclaris Therapeutics, Inc. · ACRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Powala
Officer — Chief Reg & Develop Officer
Period of report
Feb 1, 2018
Accepted (ET)
Feb 5, 2018 · 4:22 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001557746
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $22.09 | Feb 1, 2018 | A | 47,600 | A | — | Jan 31, 2028 | Common Stock | 47,600 | 47,600 | D |
| Restricted stock unitsF2,F3 | — | Feb 1, 2018 | A | 13,600 | A | — | — | Common Stock | 13,600 | 13,600 | D |
Explanation of responses
- F1The option will vest over a period of four years, with 25% of the shares underlying the option vesting on the first, second, third and fourth anniversaries of the date of grant.
- F2Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
- F3The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.